Chemical Name: N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
Therapy Type: Small Molecule
Target Type: Cholinergic System
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Daiichi Sankyo Pharmaceuticals
Approved for: None
Nefiracetam is a pyrrolidone-type agent that affects multiple neurotransmitter systems including: aminergic, glutaminergic, and cholinergic. It has been shown to stimulate α4β2-type neuronal nicotinic acetylcholine receptors, activating protein kinase C, and reducing magnesium block of the NMDA receptor 13—19. In addition, nefiracetam increased brain-derived neurotrophic factor (BDNF) expression (Ando et al., 2005) as well as regional blood flow and glucose utilization after cerebral ischemia in rats (Jin et al., 2002).
- Ando T, Takagi N, Takagi K, Kago T, Takeo S. Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats. Eur J Pharmacol. 2005 Jan 10;507(1-3):49-56. Epub 2004 Dec 23 PubMed.
- Jin J, Watabe S, Yamamoto T. Nefiracetam improves the impairment of local cerebral blood flow and glucose utilization after chronic focal cerebral ischemia in rats. Pharmacology. 2002;64(3):119-25. PubMed.
No Available Further Reading